Capricor Therapeutics (NASDAQ:CAPR) Hits New 12-Month High at $17.61

Capricor Therapeutics Inc (NASDAQ:CAPR) shares hit a new 52-week high on Tuesday . The company traded as high as $17.61 and last traded at $17.59, with a volume of 2190107 shares changing hands. The stock had previously closed at $15.21.

Analysts Set New Price Targets

CAPR has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Price Performance

The company has a market cap of $442.91 million, a PE ratio of -15.92 and a beta of 3.92. The stock has a 50 day simple moving average of $5.01 and a two-hundred day simple moving average of $5.36.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities analysts anticipate that Capricor Therapeutics Inc will post -1.14 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics during the 1st quarter worth approximately $40,000. Main Street Financial Solutions LLC raised its position in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. Rhumbline Advisers acquired a new stake in Capricor Therapeutics in the second quarter valued at $147,000. Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the 2nd quarter worth $426,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.